Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 7.5% in January

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 18,600 shares, a growth of 7.5% from the January 15th total of 17,300 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 11,200 shares, the short-interest ratio is presently 1.7 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a research note on Thursday, December 19th.

Armata Pharmaceuticals Trading Down 2.0 %

NYSEAMERICAN ARMP traded down $0.04 on Monday, hitting $1.95. 7,429 shares of the stock traded hands, compared to its average volume of 6,802. The firm has a market cap of $70.55 million, a price-to-earnings ratio of -1.19 and a beta of 0.87. Armata Pharmaceuticals has a 12 month low of $1.80 and a 12 month high of $4.48.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.